No. |
DrugBank |
Drug (Description in trials) [Number of descriptions] |
KEGG DRUG * | KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 | Acetaminophen | [8] Acetaminophen; Acetaminophen tab 650mg; Acetaminophen tablets; Acetaminophen/paracetamol; Oxycodone/acetaminophen; Paracetamol (acetaminophen); Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen; | D00217 |
[2] PTGS1, PTGS2 |
[21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
[13] 3, 6, 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
2 | Acetylsalicylic acid | [2] Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,; | D00109 |
[2] PTGS1, PTGS2 |
[21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
[10] 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
3 | Alpha-1-proteinase inhibitor | - | - |
- |
- |
[3] 231, 298, 299 |
4 | Alvelestat | [4] Alvelestat; Alvelestat (mph996); Alvelestat oral tablet - dose 1; Alvelestat oral tablet - dose 2; | - |
- |
- |
[1] 231 |
5 | Carbamazepine | [2] Carbamazepine; Drug-carbamazepine (tegretol xr); | D00252 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[1] 231 |
6 | Epinephrine | [4] Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine; | D00095 D00996 D02149 |
[9] ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
[13] AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[9] 6, 13, 46, 86, 96, 168, 226, 231, 256 |
7 | Fentanyl | [5] Dexmedetomidine and fentanyl; Fentanyl; Fentanyl citrate; Fentanyl transdermal patch; Transdermal fentanyl matrix, gabapentin; | D00320 D01399 |
[1] OPRM1 |
[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
[5] 46, 70, 85, 215, 231 |
8 | Hyaluronic acid | [5] Hyaluronic acid; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid inhalation solution; Hyaluronic acid/chondroitin sulfate; Standard care hyaluronic acid eye drops; | D08043 |
- |
- |
[7] 46, 53, 70, 97, 226, 231, 299 |
9 | Lidocaine | [8] 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine; Lidocaine injection 2%; Lidocaine patch 5%; Lidocaine releasing intravesical system - liris®; Local anesthesia (lidocaine hydrochloride); | D00358 D02086 D08127 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[10] 6, 13, 46, 84, 86, 97, 168, 226, 231, 256 |
10 | Lorazepam | [1] Lorazepam; | D00365 |
[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
[1] 231 |
11 | Midazolam | [6] Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam; | D00550 D00696 D05028 |
[16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
[10] 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
12 | Ondansetron | [1] Ondansetron; | D00456 D00678 |
[5] HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
[2] Serotonergic synapse, Taste transduction |
[1] 231 |
13 | Oxycodone | [14] Extended-release oxycodone; Oxycodone; Oxycodone by patient-controlled analgesia (pca); Oxycodone depot ”sandoz”, depot tablets; Oxycodone hydrochloride; Oxycodone naloxone prolonged release tablets; Oxycodone orion; Oxycodone/acetaminophen; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Pr oxycodone; | D03783 D05312 D05462 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[7] 6, 13, 46, 70, 226, 231, 298 |
14 | Salbutamol | [5] Nebulized combination ipratropium bromide with salbutamol; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet; | D02147 |
[1] ADRB2 |
[8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
15 | Tretinoin | [3] Pioglitazone and tretinoin; Tretinoin; Tretinoin and pioglitazone hcl; | D00094 |
[3] PML, RARA, RARB |
[12] Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
[5] 2, 63, 75, 94, 231 |
16 | Xenon | [7] Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment; Hyperpolarized 129-xenon gas; Hyperpolarized xenon; Hyperpolarized xenon gas; Xenon; Xenon contrast agent; Xenon-129; | D01901 D06339 |
- |
- |
[5] 22, 85, 228, 231, 299 |
17 | Xenon-133 | - | - |
- |
- |
[5] 22, 85, 228, 231, 299 |